BTIG Research Reaffirms “Buy” Rating for Ascentage Pharma Group International (NASDAQ:AAPG)

Ascentage Pharma Group International (NASDAQ:AAPG)‘s stock had its “buy” rating reaffirmed by analysts at BTIG Research in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $48.00 target price on the stock. BTIG Research’s price target suggests a potential upside of 98.18% from the stock’s current price.

A number of other brokerages have also recently issued reports on AAPG. Oppenheimer began coverage on Ascentage Pharma Group International in a report on Thursday, December 4th. They issued an “outperform” rating and a $45.00 target price for the company. Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. Truist Financial set a $51.00 price target on shares of Ascentage Pharma Group International in a research report on Monday, November 24th. Finally, Rodman & Renshaw began coverage on shares of Ascentage Pharma Group International in a research note on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to MarketBeat.com, Ascentage Pharma Group International currently has an average rating of “Buy” and an average target price of $48.00.

Ascentage Pharma Group International Stock Down 1.1%

Shares of NASDAQ:AAPG opened at $24.22 on Thursday. Ascentage Pharma Group International has a 52-week low of $17.56 and a 52-week high of $48.45. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 1.31. The company has a fifty day moving average of $25.13 and a 200-day moving average of $31.36.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Tema Etfs LLC bought a new stake in shares of Ascentage Pharma Group International during the 2nd quarter valued at about $610,000. UBS Group AG increased its stake in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares in the last quarter. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International during the second quarter worth about $391,000. Citadel Advisors LLC purchased a new stake in shares of Ascentage Pharma Group International in the third quarter worth approximately $383,000. Finally, XY Capital Ltd raised its position in Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after buying an additional 12,530 shares during the last quarter.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.